Article Details

TScan Closes on Series B to Develop Next-Generation Immuno-Oncology Therapies

Retrieved on: 2019-07-23 22:37:30

Tags for this article:

Click the tags to see associated articles and topics

TScan Closes on Series B to Develop Next-Generation Immuno-Oncology Therapies. View article details on hiswai:

Excerpt

<div>Investors include Novartis Venture Fund, Novartis Institutes for Biomedical Research, <b>Bessemer Venture Partners</b>, GV (formerly Google Ventures), and ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo